Drug Profile

TP 4311

Alternative Names: TP-4311

Latest Information Update: 04 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Thetis Pharmaceuticals
Developer Thetis Pharmaceuticals; University of Bonn
Class Antihyperlipidaemics; Docosahexaenoic acids; Eye disorder therapies; Small molecules
Mechanism of Action Inflammation mediator inhibitors; Lipid modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

04 Sep 2023 Discontinued - Preclinical for Postoperative ileus in Germany (IV) before September 2023 (Thetis Pharmaceuticals pipeline, September 2023)
28 Jun 2020 No recent reports of development identified for preclinical development in Postoperative-ileus in Germany (IV)
03 May 2016 Thetis Pharmaceuticals has a patent pending for TP 4311 in USA (Thetis Pharmaceuticals website; May 2016)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com